Apixaban market is projected to reach USD 2,602.97 million in forecast perion 2021-2028
Apixaban is an anticoagulant licensed by the Food and Drug Administration (FDA) for the treatment of venous thromboembolic events (blood clots) that form within a vein. Venous thromboembolic events (VTE) can happen without warning signs or symptoms, and they can go unnoticed and undetected by a healthcare provider. Pain in the leg, swelling in the ankle or foot, redness or obvious discoloration areas, rapid breathing, chest pain, and other symptoms may be associated with either deep vein thrombosis (DVT) or pulmonary embolism (PE). In individuals with nonvalvular atrial fibrillation, apixaban is used to lower the risk of stroke and systemic embolism.
Rising
therapeutic indications for apixaban, as well as an increase in the prevalence
of atrial fibrillation, venous thromboembolism, and stroke, an increase in the
number of geriatric population, an increase in the prevalence of obesity, a rise in healthcare expenditures worldwide, and an increase in government and
private organizations investing significantly in healthcare research will boost
market growth.
Development
is one of the most important reasons driving the apixaban industry, among
others. Furthermore, in the forecast period of 2021-2028, expanding potential
in emerging economies, increasing technical breakthroughs, and rising modernization
in the healthcare sector would provide new chances for the apixaban market.
In the
projection period of 2021 to 2028, the Apixaban market is predicted to reach an
estimated value of USD 2,602.97 million and increase at a potential rate of
5.22 percent. The rising prevalence of venous thromboembolism-related disorders
is a key factor driving market expansion.
However,
rising NOAC prices and weak demand in developing nations are among the primary
factors acting as restrictions, and will continue to pose a challenge to the
apixaban market over the projection period.
The Apixaban market is divided into two categories: form and distribution channel. The
growth of segments allows you to analyze specific pockets of growth and market
approaches, as well as establish your main application areas and target market
differences. The apixaban market is divided into capsules and tablets based on
the form.
The Apixaban market is also divided into hospitals, clinics, retail pharmacies, and online
pharmacies based on the distribution channel.
The apixaban the market report covers the United States, Canada, and Mexico in North America,
Peru, Brazil, Argentina, and the Rest of South America in South America,
Germany, Italy, the United Kingdom, France, Spain, the Netherlands, Belgium,
Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway,
Poland, and the Rest of Europe in Europe, Japan, China, India, South Korea,
Australia, and Singapore (MEA).
Abbott,
Sanofi, Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Aspen Holdings,
Bristol Myers Squibb Company, Eisai Co., Ltd., Fresenius Kabi AG, Hebei
Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC,
Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Novartis AG, OPOCRIN
S.P.A, SARIA SE

Comments
Post a Comment